A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases.
Adult Bone Marrow Transplantation Service Chief Sergio Giralt explains recent advances that are enabling more patients to survive the most difficult period after receiving a transplant.
Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.
A Memorial Sloan-Kettering study suggests that a new, experimental treatment could make bone marrow and stem cell transplantation safer and more effective.
“This is a celebration about your journey to return to the life you want to have,” Adult Bone Marrow Transplant Center Chief Sergio Giralt told 200 survivors at a party packed with friends and caregivers.
Sergio Giralt, MD, has been appointed Chief of the Adult Bone Marrow Transplantation Service in the Division of Hematologic Oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center.
Memorial Sloan-Kettering medical oncologist Katharine C. Hsu and colleagues have described an immune benefit of allogeneic, or donor-provided, blood stem cell transplants in patients being treated for leukemia.
Opened in the spring of 2008, a new outpatient clinic within Memorial Hospital is enabling Memorial Sloan-Kettering’s adult allogeneic bone marrow transplant service to enhance comfort and convenience for a rapidly growing patient population.
